Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies and Clinical Trials Insight 2031 Report Findings and Highlights:

Global Multispecific Antibodies Market Opportunity: USD 60 Billion By 2031
Global Multispecific Antibodies Market Growth: 2020 Till 2025: Around 40% CAGR and 432% Absolute Growth
Approved Multispecific Antibodies Dosage, Patent, Price and Sales Insight
Global, Regional, Annual, Quarterly Sales Insight: 2020 Till Q1’2026
Multispecific Antibodies Clinical Trials Insight By Company, Indication and Phase
Multispecific Antibodies In clinical Trials: > 750 Antibodies
Bispecific, Trispecific and Tetraspecific Antibodies Clinical Trials and Sales Insight
Competitive Landscape

Need For Multispecific Antibodies and Why This Report?

Multispecific antibodies, extending from standard bispecifics to the next generation of trispecific and tetraspecific antibodies, are quickly revolutionizing the therapeutic landscape. Through the ability to target multiple biological entities, this new approach can effectively address disease complexities such as tumor heterogeneity, immune evasion, and redundant signaling pathways. As current treatments based on a single biological target or even two targets continue to show challenges, multispecific antibodies could offer the next level of success in drug development.

In light of the increasing successes in developing bispecific antibodies, new opportunities arise for even more advanced and effective drug discovery and development. The inclusion of different mechanisms within a single therapeutic drug can lead to significant improvements in treating various diseases. In cancer, importantly, combining immune stimulation or immune modulation with tumor targeting can result in a more effective solution to existing treatment paradigms.

This report aims at offering a forward looking analysis of the new segment in the field of immunotherapeutic antibodies. In this case, rather than providing basic facts about this technology, the report is intended to show the areas of innovation, challenges, and the evolving competitive landscape in the development of advanced therapies.

We, at Kuick Research, have been one of the pioneers publishing reports dedicated to analyzing the global market for bispecific, trispecific, and tetraspecific antibodies over the last decade. The reason behind this lies in the considerable future market growth opportunity associated with the development of such molecules, which are expected to become one of the main drivers for next generation drugs.

Clinical Trials Insight Included In Report

Clinical development emerges as a crucial parameter for shaping the fate of multispecific antibodies. Although the current number of marketed multispecific antibodies is still relatively small, an impressive pipeline of molecules advances further in clinical trials – mostly in oncology and immunology indications.

The report delivers analytical insights about the clinical trial landscape, ranging from early phase trials to pivotal ones. It analyzes how the developers handle major difficulties associated with clinical development including dosing issues, safety concerns, and the use of biomarkers to select the right patients. In particular, special attention is paid to trials conducted in relapsed/refractory populations, wherein multispecific antibodies have to prove their clinical advantage.

These trials are examined in a variety of perspectives, such as the indication, the combination process, geographical spread, and stratification. Through an analysis of these trials in regard to their mechanism, trial design, and selection of targets, the report is able to give an indication on the likelihood of success and the development of new therapies.

Major Companies Active In RandD Of Multispecific Antibodies

The competitive environment in multispecific antibody space is dominated by both well-known pharmaceutical giants and cutting-edge biotech players. Big pharmaceutical firms like Roche, Amgen, and Johnson and Johnson capitalize on their experience in research and development, clinical trials, and commercialization to venture into more sophisticated multispecific antibody spaces, contributing to stability and certainty within the market.

Additionally, there is a rising trend of new biotech firms that innovate using their own platform technologies and new molecular structures. These innovative firms include Zymeworks, Alligator Bioscience, and ABL Bio. They are agile and their technological differentiators make them good collaboration partners and potential acquisition targets.

Technology Platforms, Collaborations and Agreements

Technological innovation plays an important role in pushing multispecific antibodies further since going beyond the bispecific approach brings with it difficulties related to stability, production, and safety. Proprietary technology platforms allow for developing antibodies with higher specificity and manufacturing efficiency. For example, QLSF Biotherapeutics has developed the TECAD (T Cell Engager with Co-Stimulation, Avidity Driven) platform for designing sophisticated multispecific molecules, while Amgen continues refining new antibody engineering processes using its BiTE platform.

Alliances and mergers are no less significant in advancing innovations in the multispecific antibody landscape. Such examples as collaboration between Boehringer Ingelheim and Simcere Pharmaceutical Group or Genmab acquiring Merus in December 2025 demonstrate how pharmaceutical companies can gain access to cutting-edge platforms while distributing risks.

In this report, we will analyze selected alliances, mergers, and licensing arrangements to show how deals are organized and what they say about future business trends.

Report Indicating Future Direction Of Multispecific Antibody Segment

The prospects for multispecific antibodies look extremely positive, backed by increased funding, pipeline developments, and ongoing innovations. With an ever-growing number of candidates progressing into advanced stages of development, the probability of obtaining regulatory approval in the coming years seems increasingly likely.

Multispecific antibody combinations are poised to make a name for themselves in this field moving forward, especially within oncology. The development of multispecific antibodies that can be used as part of combination therapies is becoming increasingly common, both as backbone treatment or as adjuvant to current treatments. There is also growth in the use of multispecific antibodies in autoimmune and inflammatory indications.

For investors interested in this sector, knowledge of innovation, development progress and positioning will prove crucial in making decisions. This report provides a curated view of these factors, enabling informed decision-making.

Research Methodology

Introduction to Next Generation Multispecific Antibodies

Next Generation Multispecific Antibody Current Clinical Development and Future Commercialization Outlook

3.1 Current Market Overview

3.2 Future Commercialization Opportunity

3.3 Next Generation Multispecific Antibody Proprietary Technologies By Company

Next Generation Multispecific Antibody Clinical Trends by Indication

4.1 Cancer

4.2 Hematological Disorders

4.3 Microbial Infections

4.4 Autoimmune and Inflammatory Disorders

4.5 Ocular Diseases

Next Generation Multispecific Antibody Clinical Development and Market Trends by Region

5.1 US

5.2 Europe

5.3 China

5.4 UK

5.5 Japan

5.6 Australia

5.7 South Korea

5.8 Canada

Approved Multispecific Antibodies – Clinical Overview, Pricing, Dosing and Sales Insight

6.1 Overview

6.2 Clinical Overview, Pricing and Dosage Insight

6.3 Sales Insight (2020 – Q1’2026)

Global Multispecific Antibodies Clinical Trials Overview

Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase

8.1 Research

8.2 Preclinical

8.3 Phase I

8.4 Phase I/II

8.5 Phase II

8.6 Phase-II/III

8.7 Phase III

8.8 Preregistration

8.9 Registered

Marketed Bispecific Antibodies Clinical Insight By Company, Country and Indication

Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase

10.1 Research

10.2 Preclinical

10.3 Phase I

10.4 Phase I/II

10.5 Phase II

10.6 Phase II/III

Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase

11.1 Preclinical

11.2 Phase I

11.3 Phase I/II

11.4 Phase II

Competitive Landscape

12.1 AbbVie

12.2 ABL Bio

12.3 Abzyme Therapeutics

12.4 Affimed Therapeutics

12.5 Akeso Biopharma

12.6 Alligator Bioscience

12.7 Amgen

12.8 APITBIO

12.9 Astellas Pharma

12.10 AstraZeneca

12.11 Aptevo Therapeutics

12.12 BioAtla

12.13 Biocytogen Pharmaceuticals

12.14 Biosion

12.15 CStone Pharmaceuticals

12.16 Diagonal Therapeutics

12.17 EpimAb Biotherapeutics

12.18 FutureGen Biopharmaceutical

12.19 Genentech

12.20 Genmab

12.21 Genor Biopharma

12.22 Gensun Biopharma

12.23 Harbour BioMed

12.24 IGM Biosciences

12.25 I-MAB Biopharma

12.26 ImmuneOnco Biopharma

12.27 ImmunoPrecise Antibodies

12.28 Innate Pharma

12.29 Innovent Biologics

12.30 Invenra

12.31 Johnson and Johnson

12.32 Kenjockety Biotechnology

12.33 LaNova Medicines Limited

12.34 Light Chain Bioscience

12.35 Linton Pharm

12.36 Lyvgen Biopharma

12.37 MacroGenics

12.38 Merck

12.39 Merus

12.40 ModeX Therapeutics (OPKO Health)

12.41 Molecular Partners

12.42 NovaRock Biotherapeutics

12.43 Numab

12.44 OPKO Health

12.45 Pfizer

12.46 Regeneron Pharmaceuticals

12.47 Revitope

12.48 Roche

12.49 Sanofi

12.50 Sichuan Baili Pharmaceutical

12.51 SystImmune

12.52 Virtuoso Therapeutics

12.53 Xencor

12.54 Y-Biologics

12.55 Zymeworks

Figure 3-1: Global – Annual Multispecific Antibody Market (US$ Million), 2020-2026

Figure 3-2: Global - Annual Multispecific Antibodies Market By Drugs (US$ Million), Q1’2026

Figure 3-3: Global - Multispecific Antibodies Market Shares By Drugs (%), Q1’2026

Figure 3-4: Global - Annual Multispecific Antibodies Market By Drugs (US$ Million), 2025

Figure 3-5: Global - Multispecific Antibodies Market Shares By Drugs (%), 2025

Figure 3-6: Global - Annual Multispecific Antibody Market By Region (US$ Million), Q1’2026

Figure 3-7: Global – Multispecific Antibody Market Shares By Region (%), Q1’2026

Figure 3-8: Global – Quarterly Multispecific Antibody Market (US$ Million), 2025

Figure 3-9: Global - Annual Multispecific Antibody Market By Region (US$ Million), 2025

Figure 3-10: Global – Multispecific Antibody Market Shares By Region (%), 2025

Figure 3-11: US – Multispecific Antibody Market (US$ Million), 2020-2025

Figure 3-12: US - Quarterly Multispecific Antibodies Market (US$ Million), 2025

Figure 3-13: ROW – Multispecific Antibody Market Value (US$ Million), 2020-2025

Figure 3-14: ROW - Quarterly Multispecific Antibodies Market (US$ Million), 2025

Figure 3-15: Global - Multispecific Antibody Market Opportunity Assessment (US$ Billion), 2026 – 2031

Figure 3-16: Multiclonics - Distinctive Characteristics

Figure 3-17: Biclonics - Format

Figure 3-18: ADAPTIR Bispecific Structure

Figure 3-19: ADAPTIR-FLEX

Figure 3-20: BEAT Platform - Multispecific Antibodies

Figure 3-21: FIT-Ig - Proprietary Bispecific Platform

Figure 3-22: BiClone format

Figure 3-23: BioAtla CABs – Features

Figure 3-24: BioAtla CABs – Benefits

Figure 3-25: IMBiologic Bispecific Antibodies - Strategy

Figure 3-26: IMBiologic Bispecific Antibodies – Mechanism Of Action

Figure 3-27: Novel HBICE

Figure 3-28: HBICE - Mechanism Of Action 1

Figure 3-29: HBICE - Mechanism Of Action 2

Figure 3-30: Phanes Therapeutics – PACbody Platform

Figure 3-31: Phanes Therapeutics – SPECpair Platform

Figure 3-32: Phanes Therapeutics – ATACCbody

Figure 3-33: Numab Therapeutics - Technology

Figure 3-34: Grabody I Platform - Mechanism Of Action

Figure 3-35: Grabody I Platform - Mechanism Of Action

Figure 3-36: 3-Step DuoBody Production Process

Figure 3-37: DuoHexaBody Molecules – Schematic

Figure 3-38: iTAb – Patented Structure

Figure 3-39: iTAb – Mechanism of Action

Figure 3-40: Synimmune - Proprietary Bispecific Antibody Format

Figure 3-41: BiTE - Structure

Figure 3-42: BiTE Molecule

Figure 3-43: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform

Figure 3-44: ALiCE – Characteristics

Figure 3-45: ALiCE - Schematic Diagram and Mechanism Of Action

Figure 3-46: Abz2 Bispecific Platform

Figure 3-47: Abz2 Bispecifics - Benefits

Figure 3-48: Neo-X-Prime Bispecific Mechanism

Figure 3-49: B-Body Bispecific Antibody - Structre

Figure 3-50: xLinkBsAb - Structure

Figure 3-51: PrecisionGATE Bispecific Antibody - Structure

Figure 3-52: Chugai Pharmaceutical - Dual-Ig Platform

Figure 3-53: EVOLVE Molecule

Figure 3-54: CD3-only Bispecifics vs. EVOLVE Trispecific Molecules

Figure 3-55: MabWorks - Multispecific Antibody Platform’s T-cell engagers

Figure 3-56: MabWorks - Multispecific Antibody Platform’s Immune-stimulatory multispecific antibodies

Figure 3-57: Marengo - TriSTAR

Figure 3-58: Merus – Multiclonics Antibodies

Figure 3-59: Merus – Triclonics Platform

Figure 3-60: Must Bio - BICSTA

Figure 3-61: Purple Biotech - CAPTN-3

Figure 3-62: Shine-On BioMedical - Trispecific T Cell Engager Antibody

Figure 3-63: Zymeworks Azymetric

Figure 3-64: DARPin Platform - Molecular Partners

Figure 3-65: ANKETandreg; Platform - Innate Pharma

Figure 3-66: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune

Figure 3-67: STEALTH – ModeX Therapeutics

Figure 3-68: MSTAR – ModeX Therapeutics

Figure 3-69: MSTAR – Salient Features

Figure 3-70: TECAD – QLSF Biotherapeutics

Figure 3-71: Multispecific VHH Antibody Drug Platform - Beijing StarMab Biomed Technology

Figure 4-1: LINKER-MM1 Phase I/II (NCT03761108) Study – Initiation and Completion Year

Figure 4-2: ELM-2 Phase II (NCT03888105) Study – Initiation and Completion Year

Figure 4-3: OLYMPIA-1 Phase III (NCT06091254) Study – Initiation and Completion Year

Figure 4-4: CPIT565A12101 Phase I (NCT05397496) Study – Initiation and Completion Year

Figure 4-5: CR109234 Phase I (NCT05652335) Study – Initiation and Completion Year

Figure 4-6: GNC-038-102 Phase I/II (NCT05192486) Study – Initiation and Completion Year

Figure 4-7: GNC-038-103 Phase I/II (NCT05485753) Study – Initiation and Completion Year

Figure 4-8: MDX-2003-101 Phase I/II (NCT07249905) Study – Initiation and Completion Year

Figure 4-9: CIBI3003A101 Phase I/II (NCT06083207) Study – Initiation and Completion Year

Figure 4-10: LBL-024-CN001 Phase I/II (NCT05170958) Study – Initiation and Completion Year

Figure 4-11: LBL-024-CN002 Phase I/II (NCT06157827) Study – Initiation and Completion Year

Figure 4-12: COMPANION-002 Phase II/III (NCT05506943) Study – Initiation and Completion Year

Figure 4-13: NbTAST-01 Phase I/II (NCT07055594) Study – Initiation and Completion Year

Figure 4-14: GNC-039-101 Phase I (NCT04794972) Study – Initiation and Completion Year

Figure 4-15: PM8002-BC011C-SCLC-R Phase II (NCT05844150) Study – Initiation and Completion Year

Figure 4-16: HARMONi-6 Phase III (NCT05840016) Study – Initiation and Completion Year

Figure 4-17: HARMONi-2 Phase III (NCT05499390) Study – Initiation and Completion Year

Figure 4-18: HARMONi-3 Phase I/II (NCT05899608) Study – Initiation and Completion Year

Figure 4-19: EMB01X201 Phase I/II (NCT05176665) Study – Initiation and Completion Year

Figure 4-20: AHAEmi Phase II (NCT05345197) Study – Initiation and Completion Year

Figure 4-21: BCDI-XII Phase I (NCT05500807) Study – Initiation and Completion Year

Figure 4-22: CL-101 Phase I/II (NCT06211634) Study – Initiation and Completion Year

Figure 4-23: HMB-001-201 Phase II (NCT07347249) Study – Initiation and Completion Year

Figure 4-24: YBSW015 Phase I (NCT05369754) Study – Initiation and Completion Year

Figure 4-25: CLN-978-SL-101 Phase I (NCT06613360) Study – Initiation and Completion Year

Figure 4-26: BBT001-001 Phase I (NCT06808477) Study – Initiation and Completion Year

Figure 4-27: BBT001-002 Phase I (NCT07239947) Study – Initiation and Completion Year

Figure 4-28: BBT002-001 Phase I (NCT06944925) Study – Initiation and Completion Year

Figure 4-29: BBT002-002 Phase I (NCT07288554) Study – Initiation and Completion Year

Figure 4-30: BBT002-003 Phase I (NCT07436949) Study – Initiation and Completion Year

Figure 4-31: BCDI-XII Phase I (NCT05500807) Study – Initiation and Completion Year

Figure 4-32: BRUNELLO Phase II/III (NCT06571045) Study – Initiation and Completion Year

Figure 4-33: BAROLO Phase II/III (NCT06957080) Study – Initiation and Completion Year

Figure 4-34: MALBEC Phase II/III (NCT06957080) Study – Initiation and Completion Year

Figure 4-35: ASKG712-CT-I-1 Phase I (NCT05456828) Study – Initiation and Completion Year

Figure 5-1: US – Approved Multispecific Antibodies

Figure 5-2: EU – Approved Multispecific Antibodies

Figure 6-1: Blincyto – Approval Year By Region

Figure 6-2: Blincyto – Patent Filing and Expiration Year

Figure 6-3: Blincyto - Treatment Regimen Cycles (Weeks)

Figure 6-4: Blincyto – Duration Of Treatment Phase and Resting Phase In Induction and Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)

Figure 6-5: Blincyto – Recommended Number Of Induction and Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL

Figure 6-6: Blincyto – Duration Of Single Induction, Consolidation, Continued Cycle and Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)

Figure 6-7: Hemlibra – Approval Years By Region

Figure 6-8: Hemlibra – Cost Per Unit and Supply Of 30 mg/mL Subcutaneous Injection By Volume (US$), May’2026

Figure 6-9: Hemlibra – Cost per Unit and Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), May’2026

Figure 6-10: Hemlibra – Recommended Loading and Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)

Figure 6-11: Rybrevant – Patent Filing and Expiration Year

Figure 6-12: Rybrevant – Price Per Unit and Supply Of Intravenous Solution (US$), May’2026

Figure 6-13: Rybrevant – Recommended Dose Per Cycle By Body Weight (mg)

Figure 6-14: Rybrevant – Dose Reduction In Patients With Weight Less Than 80 kg (mg)

Figure 6-15: Rybrevant – Dose Reduction in Patients with Weight more than 80 Kg (mg)

Figure 6-16: Vabysmo – Approval Year By Region

Figure 6-17: Rybrevant – Patent Filing and Expiration Year

Figure 6-18: Vabysmo – Price Per Unit and Supply Of Intravitreal Solution (US$), May’2026

Figure 6-19: Lunsumio – Approval Years By Region

Figure 6-20: US – Price Per Unit and Supply of Lunsumio Intravenous Solution (US$), May’2026

Figure 6-21: EU – Price Per Unit and Supply of Lunsumio Intravenous Solution (US$), May’2026

Figure 6-22: Tecvayli – Approval Years by Region

Figure 6-23: Tecvayli – Patent Acceptance and Expiration Year

Figure 6-24: US – Cost Per Unit and Supply Of Tecvayli Subcutaneous Solution (US$), May’2026

Figure 6-25: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), May’2026

Figure 6-26: Columvi – Approval Year By Region

Figure 6-27: US – Price Per Unit and Supply Of Columvi Intravenous Solution (US$), May’2026

Figure 6-28: EU – Price Of Supply Of Columvi Intravenous Solution (US$), May’2026

Figure 6-29: Epkinly – Approval Year By Region

Figure 6-30: US - Cost Per Unit and Supply Of Epkinly Subcutaneous Solution (US$), May’2026

Figure 6-31: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), May’2026

Figure 6-32: Talvey – Approval Year By Region

Figure 6-33: Talquetamab – FDA and EMA Designation Year

Figure 6-34: Talvey – Patent Acceptance and Expiration Year

Figure 6-35: US – Price Per Unit and Supply Of Talvey Intravenous Solution (US$), May’2026

Figure 6-36: EU – Price Per Supply Of Talvey Intravenous Solution (US$), May’2026

Figure 6-37: Elrexfio – Approval Year by Region

Figure 6-38: Elranatamab – FDA and EMA Designation Year

Figure 6-39: US – Price Per Unit and Supply Of Elrexfio Subcutaneous Solution (US$), May’2026

Figure 6-40: Imdelltra – Approval Year By Region

Figure 6-41: US – Price Of Supply Of Imdelltra Intravenous Powder (US$), May’2026

Figure 6-42: EU – Price Of Supply Of Imdelltra Intravenous Powder (US$), May’2026

Figure 6-43: EU – Price Of Supply Of Ordspono Intravenous Powder (US$), May’2026

Figure 6-44: US and EU – Price Per Unit and Supply Of Ziihera (US$), May’2026

Figure 6-45: Zenocutuzumab – Active Patents

Figure 6-46: US – Price Of Supply Of Bizengri Intravenous Solution (US$), May’2026

Figure 6-47: US – Price Per Unit and Supply of Lynozyfic Intravenous Solution, May’2026

Figure 6-48: Global – Blincyto Sales (US$ Million), 2020–2026

Figure 6-49: Global – Blincyto Quarterly Sales (US$ Million), 2025

Figure 6-50: US – Blincyto Sales (US$ Million), 2020-2026

Figure 6-51: US – Blincyto Quarterly Sales (US$ Million), 2025

Figure 6-52: ROW – Blincyto Sales (US$ Million), 2020-2026

Figure 6-53: ROW – Blincyto Quarterly Sales (US$ Million), 2025

Figure 6-54: Global – Hemlibra Sales (US$ Million), 2020-2026

Figure 6-55: Global – Hemlibra Quarterly Sales (US$ Million), 2025

Figure 6-56: Global – US v/s ROW Sales (US$ Million), Q1’2026

Figure 6-57: Global – US v/s ROW Sales (US$ Million), 2025

Figure 6-58: Global – Hemlibra Sales By Region (US$ Million), Q1’2026

Figure 6-59: Global – Hemlibra Sales By Region (US$ Million), 2025

Figure 6-60: Global – Hemlibra Sales By Region (%), Q12026

Figure 6-61: Global – Hemlibra Sales By Region (%), 2025

Figure 6-62: US – Hemlibra Sales (US$ Million), 2020-2026

Figure 6-63: US – Hemlibra Quarterly Sales (US$ Million), 2025

Figure 6-64: Europe – Hemlibra Sales (US$ Million), 2020-2026

Figure 6-65: Europe – Hemlibra Quarterly Sales (US$ Million), 2025

Figure 6-66: Japan – Hemlibra Sales (US$ Million), 2020-2026

Figure 6-67: Japan – Hemlibra Quarterly Sales (US$ Million), 2025

Figure 6-68: ROW – Hemlibra Sales (US$ Million), 2020-2026

Figure 6-69: ROW – Hemlibra Quarterly Sales (US$ Million), 2025

Figure 6-70: Global – Rybrevant Sales (US$ Million), 2024–2026

Figure 6-71: Global – Rybrevant Quarterly Sales (US$ Million), 2025

Figure 6-72: US – Rybrevant Sales ((US$ Million), 2024-2026

Figure 6-73: US – Rybrevant Quarterly Sales (US$ Million), 2025

Figure 6-74: ROW – Rybrevant Sales (US$ Million), 2024-2026

Figure 6-75: ROW – Rybrevant Quarterly Sales (US$ Million), 2025

Figure 6-76: Global – Vabysmo Sales (US$ Million), 2022-2026

Figure 6-77: Global – Vabysmo Quarterly Sales (US$ Million), 2025

Figure 6-78: Global – US v/s ROW Sales (US$ Million), Q1’2026

Figure 6-79: Global – US v/s ROW Sales (US$ Million), 2025

Figure 6-80: Global – Vabysmo Sales By Region (US$ Million), Q1’2026

Figure 6-81: Global – Vabysmo Sales By Region (US$ Million), 2025

Figure 6-82: Global – Vabysmo Sales By Region (%), Q1’2026

Figure 6-83: Global – Vabysmo Sales By Region (%), 2025

Figure 6-84: US – Vabysmo Sales (US$ Million), 2022-2026

Figure 6-85: US – Vabysmo Quarterly Sales (US$ Million), 2025

Figure 6-86: Europe – Vabysmo Sales (US$ Million), 2022-2026

Figure 6-87: Europe – Vabysmo Quarterly Sales (US$ Million), 2025

Figure 6-88: Japan – Vabysmo Sales (US$ Million), 2022-2026

Figure 6-89: Japan – Vabysmo Quarterly Sales (US$ Million), 2025

Figure 6-90: ROW – Vabysmo Sales (US$ Million), 2022-2026

Figure 6-91: ROW – Vabysmo Quarterly Sales (US$ Million), 2025

Figure 6-92: Global – Lunsumio Sales (US$ Million), 2022-2025

Figure 6-93: Global – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-94: Global – US v/s ROW Sales (US$ Million), Q1’2026

Figure 6-95: Global – US v/s ROW Sales (US$ Million), 2025

Figure 6-96: Global – Lunsumio Sales By Region (US$ Million), Q1’2026

Figure 6-97: Global – Lunsumio Sales By Region (US$ Million), 2025

Figure 6-98: Global – Lunsumio Sales By Region (%), Q1’2026

Figure 6-99: Global – Lunsumio Sales By Region (%), 2025

Figure 6-100: US – Lunsumio Sales (US$ Million), 2022-2026

Figure 6-101: US – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-102: Europe – Lunsumio Sales (US$ Million), 2022-2026

Figure 6-103: Europe – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-104: Japan – Lunsumio Sales (US$ Million), 2022-2026

Figure 6-105: Japan – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-106: ROW – Lunsumio Sales (US$ Million), 2022-2026

Figure 6-107: ROW – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-108: China – Kaitani Sales (US$ Million), 2022-2023

Figure 6-109: Global – Tecvayli Sales (US$ Million), 2022-2026

Figure 6-110: Tecvayli - US v/s ROW Sales (US$ Million), Q1’2025

Figure 6-111: Tecvayli - US v/s ROW Sales (US$ Million), 2025

Figure 6-112: Tecvayli - US v/s ROW Sales (%), Q1’2026

Figure 6-113: Tecvayli - US v/s ROW Sales (%), 2025

Figure 6-114: Global – Tecvayli Quarterly Sales (US$ Million), 2025

Figure 6-115: US – Tecvayli Sales (US$ Million), 2022-2026

Figure 6-116: US – Tecvayli Quarterly Sales (US$ Million), 2025

Figure 6-117: ROW – Tecvayli Sales (US$ Million), 2022-2026

Figure 6-118: ROW – Tecvayli Quarterly Sales (US$ Million), 2025

Figure 6-119: Global – Columvi Sales (US$ Million), 2023-2026

Figure 6-120: Global – Columvi Quarterly Sales (US$ Million), 2025

Figure 6-121: Global – US v/s ROW Sales (US$ Million), Q1’2026

Figure 6-122: Global – US v/s ROW Sales (US$ Million), 2025

Figure 6-123: Global – Columvi Sales By Region (US$ Million), Q1’2026

Figure 6-124: Global – Columvi Sales By Region (US$ Million), 2025

Figure 6-125: Global – Columvi Sales By Region (%), Q1’2026

Figure 6-126: Global – Columvi Sales By Region (%), 2025

Figure 6-127: US – Columvi Sales (US$ Million), 2023-2026

Figure 6-128: US – Columvi Quarterly Sales (US$ Million), 2025

Figure 6-129: Europe – Columvi Sales (US$ Million), 2023-2026

Figure 6-130: Europe – Columvi Quarterly Sales (US$ Million), 2025

Figure 6-131: ROW – Columvi Sales (US$ Million), 2023-2026

Figure 6-132: ROW – Columvi Quarterly Sales (US$ Million), 2025

Figure 6-133: Global – Epkinly Sales (US$ Million), 2023-2026

Figure 6-134: Global – Epkinly Sales Reported By Genmab (US$ Million), 2023-2026

Figure 6-135: Global – Epkinly Sales Reported By AbbVie (US$ Million), 2023-2026

Figure 6-136: Global – Epkinly Quarterly Sales (US$ Million), 2025

Figure 6-137: Global – Talvey Sales (US$ Million), 2024–2026

Figure 6-138: Global – Talvey Quarterly Sales (US$ Million), 2025

Figure 6-139: US – Talvey Sales ((US$ Million), 2024-2026

Figure 6-140: US – Talvey Quarterly Sales (US$ Million), 2025

Figure 6-141: ROW – Talvey Sales (US$ Million), 2024-2026

Figure 6-142: ROW – Talvey Quarterly Sales (US$ Million), 2025

Figure 6-143: Global – Elrexfio Sales (US$ Million), 2023-2026*

Figure 6-144: Global – Elrexfio Quarterly Sales (US$ Million), 2025

Figure 6-145: US – Elrexfio Sales (US$ Million), 2023-2026

Figure 6-146: Global – Elrexfio Quarterly Sales (US$ Million), 2025

Figure 6-147: ROW – Elrexfio Sales (US$ Million), 2023-2026

Figure 6-148: Global – Elrexfio Quarterly Sales (US$ Million), 2025

Figure 6-149: Global – Imdelltra Sales (US$ Million), 2024-2026

Figure 6-150: Global – Imdelltra Quarterly Sales (US$ Million), 2025

Figure 6-151: US – Imdelltra Sales ((US$ Million), 2024-2026

Figure 6-152: US – Imdelltra Quarterly Sales (US$ Million), 2025

Figure 6-153: ROW – Imdelltra Sales (US$ Million), 2024-2026

Figure 6-154: ROW – Imdelltra Quarterly Sales (US$ Million), 2025

Figure 6-155: Global – Ordspono Sales (US$ Million), 2026

Figure 6-156: Global – Ziihera Sales (US$ Million), 2024-2026

Figure 6-157: Global – Ziihera Quarterly Sales (US$ Million), 2025

Figure 6-158: Global – Lynozyfic Sales (US$ Million), 2026

Figure 7-1: Global – Number of Bispecific Antibodies In Clinical Pipeline By Phase, 2026 Till 2031

Figure 7-2: Global – Number Of Trispecific Antibodies Clinical Trials By Company, 2026

Figure 7-3: Global – Number Of Trispecific Antibodies Clinical Trials By Country, 2026

Figure 7-4: Global – Number Of Trispecific Antibodies Clinical Trials By Indications, 2026

Figure 7-5: Global – Number Of Trispecific Antibodies Clinical Trials By Phase, 2026

Figure 7-6: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2026

Figure 7-7: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2026

Figure 7-8: Global – Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2026

Figure 7-9: Global – Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2026

List Of Tables

Table 3-1: Multispecific Antibodies FDA Designations (Orphan, Breakthrough Therapy and Fast Track)

Table 3-2: Global Multispecific Antibodies Market – Collaborations, License Agreements and Acquisitions

Table 3-3: Global Multispecific Antibodies Market – Emerging Startups

Table 3-4: Global Multispecific Antibodies Market – Investments

Table 4-1: Hematological Cancers – Approved Multispecific Antibodies

Table 4-2: Solid Cancers – Approved Multispecific Antibodies

Table 6-1: Approved Multispecific Antibodies

Table 6-2: Blincyto – Active Patents

Table 6-3: Blincyto - Recommended Dosage and Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL

Table 6-4: Blincyto - Recommended Dosage and Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL

Table 6-5: Blincyto - Recommended Dosage and Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL

Table 6-6: Rybrevant – Premedication

Table 6-7: Rybrevant - Dose Reductions For Adverse Reactions

Table 6-8: Rybrevant - Recommended Dosage Modifications For Adverse Reactions

Table 6-9: Lunsumio – Recommended Treatment Cycles

Table 6-10: Lunsumio - Recommended Premedications

Table 6-11: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome

Table 6-12: Tecvayli - Dosing Schedule

Table 6-13: Tecvayli - Recommended Dosage Modifications For Adverse Reactions

Table 6-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)

Table 6-15: Columvi - Premedications To Be Administered

Table 6-16: Columvi - Recommendations For Management Of Cytokine Release Syndrome

Table 6-17: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)

Table 6-18: Columvi - Recommended Dosage Modifications For Other Adverse Reactions

Table 6-19: Epkinly - Dosage Schedule

Table 6-20: Epkinly - Recommendations For Management Of Cytokine Release Syndrome

Table 6-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 6-22: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions

Table 6-23: Talvey - Weekly Dosing Schedule

Table 6-24: Talvey – Biweekly Dosing Schedule

Table 6-25: Talvey - Recommendations For Management of CRS

Table 6-26: Talvey - Recommendations For Management Of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 6-27: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)

Table 6-28: Talvey - Recommended Dosage Modifications For Other Adverse Reactions

Table 6-29: Elrexfio - Dosing Schedule

Table 6-30: Elrexfio – Recommendations For Management Of CRS

Table 6-31: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions

Table 6-32: Kaitani - Recommended Dose modifications

Table 6-33: Ordspono - Recommended Dose

Table 6-34: Ordspono - Premedications and Post-Medications For Patients With r/r FL Or r/r DLBCL

Table 6-35: Ordspono - Recommendations For Management Of Cytokine Release Syndrome

Table 6-36: Ziihera - Dosage Modifications For Adverse Reactions

Table 6-37: Bizengri - Premedications Prior To Infusions

Table 6-38: Bizengri - Premedications Prior to Infusions

Table 6-39: Bizengri - Recommended Dosage Modifications and Management For Adverse Reactions

Table 6-40: Korjuny - Dosing Schedule

Table 6-41: Lynozyfic - Dosing Schedule

Table 6-42: Lynozyfic - Recommendations for Restarting Therapy After a Dose Delay

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies and Clinical Trials Insight 2031

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected